Keytruda
Merck’s $32 Billion Gambit: Decoding the High-Stakes Pursuit of a Cancer-Fighting Pioneer
Merck’s potential $32bn acquisition of Revolution Medicines signals a major shift in the oncology market. A deep dive into the finance and science behind the deal.